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Abstract
Although p53 mutations are common in solid tumors, such mutations are found at a lower frequency in
hematologic malignancies. In the genetic disorder Fanconi anemia (FA), p53 has been proposed as an important
pathophysiological factor for two important hematologic hallmarks of the disease: bone marrow failure and
leukemogenesis. Here we show that low levels of the p53 protein enhance the capacity of leukemic stem cells from
FA patients to repopulate immunodeficient mice. Furthermore, boosting p53 protein levels with the use of the
small molecule Nutlin-3 reduced leukemia burden in recipient mice. These results demonstrate that the level of p53
protein plays a crucial role in FA leukemogenesis.
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Fanconi anemia (FA) is a genetic disorder caused by defects in at least 21 genes (FANCA-V) [1–6]. Patients
with mutations in any of these genes develop a FA
phenotype characterized by a variety of symptoms,
including skeletal and developmental defects, bone
marrow (BM) failure, and a high predisposition to cancer [1, 7, 8]. One of the common clinical features of FA
is hematologic manifestations, possibly due to defects in
hematopoietic stem cells (HSCs) [9–11]. A majority of
FA patients invariably experience progressive BM failure,
and oftentimes progress to myelodysplastic syndrome
(MDS) and acute myeloid leukemia (AML) [1, 12–14].
Marrow dysfunction, which occurs at an early stage, is
associated with HSC loss and accounts for the majority
of FA childhood mortality [15–17]. In addition, FA patients are at extremely high risk of developing AML and
solid tumors [12, 13].
Upregulation of the tumor suppressor p53 has been
shown to play a role in certain hematologic diseases,
such as BM failure syndromes and MDS. Specifically,
* Correspondence: wei.du@hsc.wvu.edu; qishen.pang@cchmc.org
1
Department of Pharmaceutical Sciences, West Virginia University School of
Pharmacy, Morgantown, WV 26506, USA
2
Division of Experimental Hematology and Cancer Biology, Cincinnati
Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH
45229, USA
Full list of author information is available at the end of the article

upregulation of p53 function, due to specific genetic
lesions in ribosomal biogenesis, leads to apoptosis of
erythroid precursors, resulting in pathogenetic
features of Diamond–Blackfan anemia (DBA),
Schwachman–Bodian–Diamond syndrome (SBDS) and
5q-MDS [18–22]. In FA, it has been reported that
p53 deficiency increased cancer development in patients with FA and FA mice [23–26]. Conversely, p53
overactivation caused HSPC depletion in the BM of
FA patients [27]. In this study, we demonstrate that
the level of p53 protein is critical for the leukemic
stem cells from FA patients to repopulate immunodeficient mice.
To examine the functional relevance of p53 expression
in human FA leukemia cells in vivo, we established a FA
AML xenotransplant model using primary samples from
FA patients with AML and the humanized immunodeficient mouse strain NSGS, which expresses transgenic
cDNAs encoding human SCF, GM-CSF, and IL-3 [28].
We first tested the engraftment of three healthy and five
AML patient samples with different levels of p53 proteins
(Fig. 1a). We found that only two FA patient samples
(AML-3 and AML-4) resulted in > 5% human chimeras at
12 weeks post-transplant (Fig. 1b). Additionally, it appeared that AML-3 and AML-4 donor cells underwent
myeloid expansion in NSGS recipients (Fig. 1c). We then
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Fig. 1 Effect of p53 protein level on human FA leukemia cells. a The levels of p53 protein in FA AML cells. BM cells from three healthy donors
and five FA AML patients were subjected to immunoblot analysis using antibodies specific for total p53, phosphor-p53 (P-p53), or β-actin. The relative levels
of total p53 or of P-p53 to β-actin are indicated below the blot. b Comparison of human cells engrafted in the BM of NSGS recipient mice. Mice were
transplanted by intra-femoral injection with 1–3 × 106 BM cells from three healthy donors and five FA AML patients. Assessment of xenografts in the BM of
the recipient mice was performed 12 weeks after transplantation by BM aspiration and flow cytometry (n = 5 per group). c BM cells from the recipient
mice in b were subjected to flow cytometric analysis for human cell contents 12 weeks post-transplant. Quantification of myeloid (CD33+) and lymphoid
(CD19+) cells in total human engraftment (hCD45+) (n = 5 per group). d Survival of transplant recipients. Cells (5 × 106) isolated from the bone marrow of
the primary recipients in b were injected intrafemorally into each NSGS secondary recipient mouse (n = 6–10 for each group). The survival of recipient
mice was analyzed with a Kaplan–Meier plot. e The levels of p53 protein in human-derived BM cells (hCD45+) from three surviving recipients (non-leuk)
and three leukemic recipients (Leuk) transplanted with the AML-4 cells were analyzed by immunoblotting using antibodies for p53 or β-actin. The relative
levels of p53 to β-actin are indicated below the blot. The error bars and asterisks in Fig. 1c represent means ± SD and ∗p < 0.05; ∗∗p < 0.01,respectively

performed secondary transplantation to examine the effect
of p53 on the ability of the FA AML leukemic stem cells
(LSCs) to repopulate the NSGS mice. All eight of the secondary recipients of AML-3 cells died of leukemia within
180 days (Fig. 1d). This indicates that the expanded donor
AML-3 cells in the primary recipients contained pre-LSCs
that induced leukemia in the secondary recipients. While
half of the AML-4 secondary recipients (3/6) died of
leukemia, three AML-4 secondary recipients survived for
200 days after transplant (Fig. 1d). Interestingly, humanderived BM cells (hCD45+) from these three surviving
recipients expressed higher levels of p53 than the other
three leukemic recipients (Fig. 1e). Thus, the level of p53
protein determines the capacity of the LSCs from FA
patients to repopulate immunodeficient mice.
The observation that primary FA AML cells with lower
levels of p53 induced an earlier onset of leukemia in mice
than those with higher p53 levels prompted us to test
whether targeted increase of the p53 protein level could
ameliorate the FA leukemia burden. Nutlin-3 is a small
molecule antagonist of the E3 ubiquitin protein ligase

MDM2 that leads to p53 stabilization and has been used in
mouse models extensively to reactivate p53 in vivo [29, 30].
We treated the primary recipient mice using a published
protocol [31]. Specifically, we treated the mice with Nutlin3 at a dose of 50 mg/kg daily beginning at 6 weeks posttransplant for 2 weeks, and analyzed the recipients for p53
protein levels and leukemia development in the secondary
recipients. We chose primary recipients of AML-3 because
this leukemia sample showed low levels of the p53 protein
and high xenograft potential (Fig. 2a, b). Nutlin-3 treatment delayed FA leukemia development in the secondary recipient mice, as evidenced by significantly
reduced splenomegaly (Fig. 2a) and myeloid expansion
(Fig. 2b). We confirmed that Nutlin-3 treatment
elevated the p53 protein level in human-derived
(hCD45+) BM cells of the recipient mice (Fig. 2c).
When transplanted into secondary recipient mice, the
pre-leukemic cells from the Nutlin-3-treated primary recipient mice showed much less potency in the development of leukemia than vehicle control (Fig. 2d). Thus,
increased p53 protein levels by Nutlin-3 treatment
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Fig. 2 Targeted increase of p53 protein level ameliorates FA leukemia burden. a Nutlin-3 treatment ameliorates splenomegaly. We transplanted
1–3 × 106 BM cells from the AML-3 patient by intra-femoral injection into sublethally irradiated NSGS recipient mice. The mice were treated with
Nutlin-3 at a dose of 50 mg/kg daily beginning at 6 weeks post-transplant for 2 weeks. Quantification of spleen weights and representative spleen
images of the recipient mice are shown (n = 6 per group). b Nutlin-3 treatment inhibits myeloid expansion. BM cells from the recipient mice in a were
subjected to flow cytometric analysis for human cell contents. Quantification of myeloid (CD33+) cells in total human engraftment (hCD45+) is shown
(n = 6 mice per group). c Nutlin-3 treatment elevates p53 protein level. The levels p53 protein in human-derived BM cells (hCD45+) from three
vehicle-treated and three Nutlin-3-treated recipient mice in a were analyzed by immunoblotting using antibodies for p53 or β-actin. The relative levels
of p53 to β-actin are indicated below the blot. d Nutlin-3 treatment delays leukemia development. Cells (5 × 106) isolated from the BM of the primary
recipients in a were injected intrafemorally into each NSGS secondary recipient m ouse (n = 6–9 for each group). Survival of the recipients was
monitored and plotted by Kaplan–Meier curve method. The error bars and asterisks in Fig. 2a, b represent means ± SD and ∗p < 0.05, respectively

ameliorated the FA leukemia burden. However, it should
be noted that 60% of the Nutlin-3-treated recipient mice
still died of leukemia, suggesting that more factors are at
play than just the level of p53 protein.
In summary, we used primary patient samples to examine
the potential link between the status of p53 and FA
leukemogenesis. We showed that reduced levels of p53 in
FA AML correlate not only with the enhanced ability of the
pre-LSCs to repopulate immunodeficient mice but also
with increased myeloid expansion and leukemia development. These results are consistent with the well-established
roles of p53 in genomic stability, cell cycle arrest, and apoptosis. We also demonstrated that the small-molecule
MDM2 inhibitor Nutlin-3, which effectively elevated p53
protein levels in FA AML cells, significantly diminished
leukemia burden in our FA AML xenotransplant model.
Encouragingly, Nutlin-3 has been used in early clinical trials
for cancer indications [32], suggesting that a reactivationbased p53 manipulation approach for FA leukemia could
be readily translatable to clinical studies. While our results
caution targeting overactive p53 in ameliorating FA HSC
loss, restoring p53 activity in FA pre-leukemic HSCs, capable of preventing leukemic transformation, is worthy of investigation as a new avenue for FA leukemia.
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